Histamine release from tissue mast cells

Histamine release from tissue mast cells is a physiological process and a key effector mechanism in allergic and inflammatory responses (StatPearls, 2023). It is typically initiated when allergens cross-link immunoglobulin E (IgE) molecules bound to the high-affinity IgE receptor (FcεRI) on the mast cell surface, triggering a signal transduction cascade that results in the exocytosis of secretory granules (PubMed, PMID: 16751538). These granules contain histamine, a potent biogenic amine that mediates vasodilation, increased vascular permeability, and bronchoconstriction by binding to specific histamine receptors (H1-H4) (NIH, 2022). This process plays a central role in the pathogenesis of diseases such as asthma, allergic rhinitis, and anaphylaxis. Pharmacological intervention often focuses on mast cell stabilizers, such as cromolyn sodium, which prevent the release of these mediators, or monoclonal antibodies like omalizumab that neutralize IgE to prevent mast cell activation (PubChem, 2024). While not a single molecular target, this process serves as a critical phenotypic endpoint for drug discovery in allergy and immunology. Monitoring this process is often done via biomarkers like serum tryptase or histamine levels in clinical and research settings (StatPearls, 2023).

Other names

Mast cell degranulationMast cell histamine secretionType I hypersensitivity effector phase

Inhibition of mast cell degranulation (mast cell stabilization) or prevention of IgE-mediated activation of mast cells (StatPearls, 2023; PubChem, 2024).